Thursday, November 19, 2026

Structure-guided #design of a dual-antigen #mRNA #vaccine conferring broad protection against #Henipaviruses

 


Abstract

Henipaviruses (HNVs), including Nipah virus (NiV) and Hendra virus (HeV), are zoonotic paramyxoviruses with high case fatality rates and pandemic potential. Despite their threat, no licensed vaccines are currently available for human use. Here, we present a structure-guided mRNA vaccine strategy that overcomes key challenges in antigen stability, fusogenicity, and cross-protective efficacy. Using rationally engineered NiV F glycoproteins stabilized in the prefusion conformation, we identify a lead candidate (F-205) that abolishes syncytium formation and elicits high prefusion-specific antibody titers. Through systematic combinatorial screening, we determine that co-delivery of F-205 (NiV-M) and G (NiV-B) antigens via mRNA–lipid nanoparticles induces potent neutralizing and cellular immune responses. In stringent golden hamster challenge models, this vaccine confers complete survival against lethal NiV-M, NiV-B and HeV challenge, with viral RNA undetectable in lung, spleen and brain after NiV challenge and significantly reduced viral burden after HeV challenge. We also introduce surrogate assays to assess F conformation and fusion activity under standard biosafety conditions, enabling iterative antigen optimization without live-virus handling. This study defines a broadly protective, mechanistically informed vaccine platform for HNVs and provides a generalizable framework for rational design of mRNA vaccines targeting class I fusion viruses.


Source: Nature Communications, https://doi.org/10.1038/s41467-026-79459-9

____

No comments:

Post a Comment

My New Space

Most Popular Posts